{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:04:13Z","timestamp":1789502653704,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["AMED (22ck0106251h0003)"],"award-info":[{"award-number":["AMED (22ck0106251h0003)"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12185-023-03686-9","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T05:02:12Z","timestamp":1702443732000},"page":"130-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)"],"prefix":"10.1007","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-4470","authenticated-orcid":false,"given":"Kensuke","family":"Usuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumihisa","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Sezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayuki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Tomikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Mugitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kajiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Asou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Katsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"issue":"2","key":"3686_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3324\/haematol.2012.064014","volume":"98","author":"M Maynadi\u00e9","year":"2013","unstructured":"Maynadi\u00e9 M, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98(2):230\u20138.","journal-title":"Haematologica"},{"issue":"9972","key":"3686_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","volume":"385","author":"C Allemani","year":"2015","unstructured":"Allemani C, et al. Global surveillance of cancer survival 1995\u20132009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977\u20131010.","journal-title":"Lancet"},{"issue":"6","key":"3686_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2188\/jea.JE20140042","volume":"24","author":"D Chihara","year":"2014","unstructured":"Chihara D, et al. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014;24(6):469\u201373.","journal-title":"J Epidemiol"},{"issue":"2","key":"3686_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/bjc.1996.354","volume":"74","author":"M Maynadi\u00e9","year":"1996","unstructured":"Maynadi\u00e9 M, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996;74(2):288\u201390.","journal-title":"Br J Cancer"},{"issue":"8","key":"3686_CR5","first-page":"905","volume":"89","author":"U Germing","year":"2004","unstructured":"Germing U, et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica. 2004;89(8):905\u201310.","journal-title":"Haematologica"},{"issue":"19","key":"3686_CR6","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724\u201334.","journal-title":"Blood"},{"issue":"1","key":"3686_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3324\/haematol.2010.026252","volume":"96","author":"M Maynadi\u00e9","year":"2011","unstructured":"Maynadi\u00e9 M, et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d\u2019Or (Burgundy, France). Haematologica. 2011;96(1):55\u201361.","journal-title":"Haematologica"},{"issue":"12","key":"3686_CR8","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","volume":"35","author":"J Neukirchen","year":"2011","unstructured":"Neukirchen J, et al. Incidence and prevalence of myelodysplastic syndromes: data from the D\u00fcsseldorf MDS-registry. Leuk Res. 2011;35(12):1591\u20136.","journal-title":"Leuk Res"},{"issue":"5","key":"3686_CR9","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ejca.2013.12.002","volume":"50","author":"AG Dinmohamed","year":"2014","unstructured":"Dinmohamed AG, et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Eur J Cancer. 2014;50(5):1004\u201312.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3686_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.leukres.2014.11.025","volume":"39","author":"AG Dinmohamed","year":"2015","unstructured":"Dinmohamed AG, et al. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. Leuk Res. 2015;39(2):177\u201382.","journal-title":"Leuk Res"},{"issue":"1","key":"3686_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","volume":"112","author":"DE Rollison","year":"2008","unstructured":"Rollison DE, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45\u201352.","journal-title":"Blood"},{"issue":"26","key":"3686_CR12","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","volume":"117","author":"CR Cogle","year":"2011","unstructured":"Cogle CR, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121\u20135.","journal-title":"Blood"},{"issue":"3","key":"3686_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/bjh.13414","volume":"171","author":"AG Dinmohamed","year":"2015","unstructured":"Dinmohamed AG, et al. Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012. Br J Haematol. 2015;171(3):436\u20139.","journal-title":"Br J Haematol"},{"issue":"10","key":"3686_CR14","first-page":"1400","volume":"91","author":"KJ Phekoo","year":"2006","unstructured":"Phekoo KJ, et al. The incidence and outcome of myeloid malignancies in 2112 adult patients in southeast England. Haematologica. 2006;91(10):1400\u20134.","journal-title":"Haematologica"},{"issue":"17","key":"3686_CR15","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","volume":"28","author":"SL Goldberg","year":"2010","unstructured":"Goldberg SL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847\u201352.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3686_CR16","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931\u201342.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3686_CR17","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1182\/bloodadvances.2020003381","volume":"5","author":"J Rozema","year":"2021","unstructured":"Rozema J, et al. Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study. Blood Adv. 2021;5(5):1344\u201351.","journal-title":"Blood Adv"},{"key":"3686_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"2","key":"3686_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3324\/haematol.2012.063602","volume":"98","author":"D Pulte","year":"2013","unstructured":"Pulte D, et al. Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica. 2013;98(2):222\u20139.","journal-title":"Haematologica"},{"key":"3686_CR20","unstructured":"Swerdlow SCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. 2008: WHO Press."},{"key":"3686_CR21","unstructured":"Swerdlow SCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. 2017: WHO Press"},{"issue":"6","key":"3686_CR22","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079\u201388.","journal-title":"Blood"},{"issue":"12","key":"3686_CR23","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454\u201365.","journal-title":"Blood"},{"issue":"23","key":"3686_CR24","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","volume":"25","author":"L Malcovati","year":"2007","unstructured":"Malcovati L, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503\u201310.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3686_CR25","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3324\/haematol.2011.044602","volume":"96","author":"L Malcovati","year":"2011","unstructured":"Malcovati L, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic scoring system (WPSS). Haematologica. 2011;96(10):1433\u201340.","journal-title":"Haematologica"},{"issue":"1","key":"3686_CR26","first-page":"52","volume":"6","author":"C Aul","year":"1992","unstructured":"Aul C, et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6(1):52\u20139.","journal-title":"Leukemia"},{"issue":"7","key":"3686_CR27","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","volume":"128","author":"M Pfeilst\u00f6cker","year":"2016","unstructured":"Pfeilst\u00f6cker M, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128(7):902\u201310.","journal-title":"Blood"},{"issue":"3","key":"3686_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"3686_CR29","first-page":"219","volume":"52","author":"M Ohta","year":"2009","unstructured":"Ohta M. Management of anemia in the elderly. JMAJ. 2009;52(4):219\u201323.","journal-title":"JMAJ"},{"issue":"15","key":"3686_CR30","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.ejca.2015.08.003","volume":"51","author":"R De Angelis","year":"2015","unstructured":"De Angelis R, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000\u20132007: results of EUROCARE-5 population-based study. Eur J Cancer. 2015;51(15):2254\u201368.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3686_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/leu.2015.188","volume":"30","author":"AG Dinmohamed","year":"2016","unstructured":"Dinmohamed AG, et al. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989\u20132012. Leukemia. 2016;30(1):24\u201331.","journal-title":"Leukemia"},{"key":"3686_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","volume":"34","author":"AM Zeidan","year":"2019","unstructured":"Zeidan AM, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1\u201315.","journal-title":"Blood Rev"},{"issue":"1","key":"3686_CR33","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2352-3026(17)30232-6","volume":"5","author":"A Miranda-Filho","year":"2018","unstructured":"Miranda-Filho A, et al. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol. 2018;5(1):e14\u201324.","journal-title":"Lancet Haematol"},{"issue":"1","key":"3686_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood.V74.1.395.395","volume":"74","author":"GF Sanz","year":"1989","unstructured":"Sanz GF, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74(1):395\u2013408.","journal-title":"Blood"},{"issue":"19","key":"3686_CR35","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428\u201336.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3686_CR36","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3324\/haematol.2019.218677","volume":"105","author":"J Woo","year":"2020","unstructured":"Woo J, et al. Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia. Haematologica. 2020;105(3):652\u201360.","journal-title":"Haematologica"},{"issue":"21","key":"3686_CR37","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/jnci\/djn349","volume":"100","author":"MA Sekeres","year":"2008","unstructured":"Sekeres MA, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100(21):1542\u201351.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3686_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3324\/haematol.2011.049130","volume":"97","author":"AJ Davidoff","year":"2012","unstructured":"Davidoff AJ, et al. Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes. Haematologica. 2012;97(1):128\u201332.","journal-title":"Haematologica"},{"issue":"3","key":"3686_CR39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332.","journal-title":"Lancet Oncol"},{"issue":"12","key":"3686_CR40","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1038\/leu.2015.220","volume":"29","author":"AG Dinmohamed","year":"2015","unstructured":"Dinmohamed AG, et al. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry. Leukemia. 2015;29(12):2449\u201351.","journal-title":"Leukemia"},{"issue":"9","key":"3686_CR41","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/leu.2015.115","volume":"29","author":"T Bernal","year":"2015","unstructured":"Bernal T, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015;29(9):1875\u201381.","journal-title":"Leukemia"},{"issue":"5","key":"3686_CR42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/bjh.14305","volume":"175","author":"AM Zeidan","year":"2016","unstructured":"Zeidan AM, et al. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016;175(5):829\u201340.","journal-title":"Br J Haematol"},{"issue":"6","key":"3686_CR43","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjh.15273","volume":"181","author":"L Mozessohn","year":"2018","unstructured":"Mozessohn L, et al. Azacitidine in the \u201creal-world\u201d: an evaluation of 1101 higher-risk myelodysplastic syndrome\/low blast count acute myeloid leukaemia patients in Ontario. Canada Br J Haematol. 2018;181(6):803\u201315.","journal-title":"Canada Br J Haematol"},{"issue":"14","key":"3686_CR44","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","volume":"118","author":"P Fenaux","year":"2011","unstructured":"Fenaux P, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765\u201376.","journal-title":"Blood"},{"issue":"5","key":"3686_CR45","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/leu.2012.369","volume":"27","author":"A Kuendgen","year":"2013","unstructured":"Kuendgen A, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia. 2013;27(5):1072\u20139.","journal-title":"Leukemia"},{"issue":"11","key":"3686_CR46","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.leukres.2011.05.034","volume":"35","author":"F Le Bras","year":"2011","unstructured":"Le Bras F, et al. Treatment by lenalidomide in lower risk myelodysplastic syndrome with 5q deletion\u2013the GFM experience. Leuk Res. 2011;35(11):1444\u20138.","journal-title":"Leuk Res"},{"issue":"2","key":"3686_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjh.12876","volume":"166","author":"J S\u00e1nchez-Garc\u00eda","year":"2014","unstructured":"S\u00e1nchez-Garc\u00eda J, et al. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. Br J Haematol. 2014;166(2):189\u2013201.","journal-title":"Br J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03686-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03686-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03686-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T15:31:10Z","timestamp":1706715070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03686-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["3686"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03686-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"assertion":[{"value":"26 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kensuke Usuki has received research funding from Astellas, AbbVie, Bristol-Myers Squibb, Janssen, Ono, Otsuka, Chugai, Aperis, Yakult, MSD, Amgen, Alxion, Incyte, Eisai, Kyowa-Kirin, Sanofi, SymBio, Celgene, Daiichi Sankyo, Sumitomo-Dainippon, Nippon Shinyaku, Novartis, Mundi, and Takeda, has served on speaker bureaus for Novartis, Abbvie, Alexion, Incyte, Ono, Kyowa-Kirin, Sanofi, Takeda, Nippon-Shinyaku, Pfizer, and Bristol-Myers Squibb, and has served on consulting bureaus for Astellas, Amgen, Alnylam Japan, Alexion, Eisai, Otsuka, Ohara, Kyowa-Kirin, Sanofi, Sando, SymBio, Takeda, Chugai, and Nippon Shinyaku; Hisayuki Yokoyama has served on speaker bureaus for Astellas Pharma; Hiroshi Handa received research funding from Kyowa-Kirin Pharmaceutical, Chugai Pharmaceutical, and Daiichi Sankyo; Shuichi Ota has served on speaker bureaus for Novartis, Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, AstraZeneca, Janssen Pharmaceutical K.K., and Abbvie; Katsumichi Fujimaki has served on speaker bureaus for Otsuka Pharmaceuticals; Kensuke Kojima has served on speaker bureaus for Janssen, AstraZeneca, and Abbvie; Tomohiro Kajiguchi has served on speaker bureaus for Janssen Pharmaceutical, Novartis, Otsuka Pharmaceutical, Ono Pharmaceutical, Nippon Shinyaku, Sanofi, Abbvie, Pfizer, Bristol-Myers Squibb, Kyowa-Kirin, Chugai Pharmaceutical, AstraZeneca, Takede Pharmaceuticals, and Mundipharma; Norio Asou received research funding from Chugai Pharmaceutical, Sumitomo Dainippon Pharma, and Eisai and has served on Advisory Board for Nippon Shinyaku, and Novartis Pharma; Noriko Usui has served on Advisory Board for Nippon Shinyaku, AbbVie, and Daiichi Sankyo, and has served on consulting bureaus for CMIC Co., Ltd.; Itaru Matsumura received research funding from Ono Pharmaceutical, Janssen Pharmaceutical, Nippon Shinyaku, Kyowa-Kirin, Sumitomo Dainippon Pharma, Shionogi, Teijin Pharma, Boehringer Ingelheim, Sanofi, Chugai Pharmaceutical, Eisai, MSD, Asahi Kasei Pharma, Astellas Pharma, Takeda Pharmaceutical, Nihon Pharmaceutical, Daiichi Sankyo, AbbVie, Taiho Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, CSL Behring, Mundipharma, Ayumi Pharmaceutical, Eli Lilly Japan, Actelion Pharmaceuticals Japan, and Amgen BioPharma, has served on speaker bureaus for Bristol-Myers Squibb (Celgene), Novartis Pharmaceuticals, Otsuka Pharmaceutical, Pfizer Japan, Janssen Pharmaceutical, Astellas Pharma, Takeda Pharmaceutical, Daiichi Sankyo, Ono Pharmaceutical, Chugai Pharmaceutical, AstraZeneca, SymBio Pharmaceuticals, AbbVie, Amgen BioPharma, and has served on consulting bureaus for Otsuka Pharmaceutical; Yasushi Miyazaki has served on speaker bureaus for Novartis, Abbvie, Nippon-Shinyaku, Astellas, Sumitomo Pharma, and Synbio; Shigeki Ohtake, Sumihisa Honda, Mitsuhiro Matsuda, Atsushi Wakita, Yuichiro Nawa, Ken Takase, Akio Maeda, Nobuo Sezaki, Satoru Takada, Daiki Hirano, Tatsuki Tomikawa, Masahiko Sumi, Shingo Yano, Hiroyuki Fujita, Atsuko Mugitani, Ko Fujimoto, Yuichi Ishikawa, Akira Katsumi, Hitoshi Kiyoi have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}